Ledyard National Bank Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

Ledyard National Bank trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 2.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,984 shares of the company’s stock after selling 1,255 shares during the quarter. Ledyard National Bank’s holdings in Sanofi were worth $2,138,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Clearbridge Investments LLC grew its holdings in Sanofi by 8.4% during the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock valued at $9,904,000 after purchasing an additional 14,362 shares during the period. Dynamic Advisor Solutions LLC bought a new position in Sanofi during the fourth quarter valued at $2,104,000. Soros Fund Management LLC bought a new position in Sanofi during the third quarter valued at $11,533,000. International Assets Investment Management LLC bought a new position in Sanofi during the fourth quarter valued at $4,704,000. Finally, Clear Street Markets LLC grew its holdings in Sanofi by 352.8% during the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock valued at $6,983,000 after purchasing an additional 101,430 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

NASDAQ SNY traded down $0.04 during trading hours on Monday, reaching $49.09. 3,285,409 shares of the stock traded hands, compared to its average volume of 2,011,168. The stock has a 50 day simple moving average of $47.77 and a two-hundred day simple moving average of $48.28. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The company has a market cap of $124.18 billion, a price-to-earnings ratio of 24.67, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. On average, analysts predict that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 69.35%.

Analysts Set New Price Targets

A number of research firms have recently commented on SNY. Morgan Stanley began coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.